Download Free Medical Movement Disorders PowerPoint Presentation

Movement Disorders PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Movement Disorders” by Mary Quiceno, MD.

This medical PowerPoint presentation is about movement disorders, a group of neurological conditions that affect the ability to control movements. These disorders can affect different parts of the body, including the limbs, face, and trunk, and can range from mild to severe.

There are many types of movement disorders, including:

Parkinsons disease: A progressive disorder that affects movement, often causing tremors, rigidity, and difficulty with balance and coordination.
Huntingtons disease: A genetic disorder that affects movement, causing uncontrolled movements, balance problems, and cognitive decline.
Dystonia: A condition that causes involuntary muscle contractions, leading to repetitive or twisting movements.
Tourette syndrome: A neurological disorder that causes involuntary movements and vocalizations, called tics.
Essential tremor: A common condition that causes tremors, usually in the hands or arms, but can also affect the head and voice.
Ataxia: A disorder that affects coordination and balance, often causing difficulty with walking and performing fine motor tasks.

Treatment for movement disorders depends on the specific condition and the severity of the symptoms. It may include medications, physical therapy, surgery, or a combination of these approaches.

Tags : movement disorders, neurological conditions, Parkinsons disease, Essential tremor, Dystonia, Huntingtons disease, Tourette syndrome, Restless legs syndrome, Neurology, Neurology PowerPoint presentation

Published on : Jun 20, 2023 | Views : 781 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Movement Disorders Mary Quiceno, M.D. Neurology
Slide 2-

Hypokinetic & HyperkineticMovement Disorders Parkinson’s disease Parkinson’s Plus Syndromes PSP MSA SND OPCA CBD AD w/Lewy bodies LBD Tremor Dystonia Myoclonus Chorea Tics Akathisia Stereotypy RLS
Slide 3-

Basal Ganglia
Slide 4-

What is Parkinson's Disease? Parkinsonism is the name given to a collection of symptoms and signs consisting of: Tremor Rigidity Bradykinesia Unsteady gait
Slide 5-

Parkinsonism Many neurological disorders have features of parkinsonism. When parkinsonism occurs without any other neurological abnormalities, and there is no recognizable cause of it, the disorder is termed Parkinson's disease after the English physician who first described it fully in 1817.
Slide 6-

Evaluation by a neurologist is important for several reasons: All tremors are not Parkinson’s disease. There are many causes of tremor. It should not be assumed that someone has PD unless the tremor has all the features of the tremor that is known to occur in PD and other causes of tremor have been excluded. Parkinsonism is a symptom of many disorders. There are a variety of disorders in which parkinsonism occurs without obvious cause, but these disorders usually have additional features that distinguish them from classic PD. Such a distinction is important because the long-term outlook may differ and the treatment options may be different.
Slide 7-

Parkinsonism Exclusion criteria for PD Neuroleptics Toxin exposure (MPTP, CO, Mn, Methanol) Encephalitis Stroke Head injuries Early and severe dementia or autonomic dysfunction Levodopa non-responder
Slide 8-

Drug-induced Parkinsonism More common in elderly and women Symmetric onset of bradykinesia, tremor, and/or rigidity Onset within a few days to 3 months in 90% of affected patients Stop drug, try anticholingeric therapy New and Old Antipsychotics Risperdal Haldol Benzamides Reglan Phenothiazines Compazine Phenergan Others causing mainly postural tremors: Lithium Depakote Amiodarone
Slide 9-

How is Parkinson's Disease Treated? A number of treatment approaches help patients with Parkinson's disease. General lifestyle modifications (rest and exercise) Dietary considerations Physical therapy and speech therapy Medications and surgery Replace the dopamine, increase the lifetime of the dopamine at the synapse, or stimulate the dopamine receptors.
Slide 10-

Medications for Parkinson's disease Levodopa (carbidopa/levodopa; Sinemet) Reduces the symptoms. Carbidopa prevents peripheral break down of levodopa. Minimum of 75 mg/d to avoid nausea. Treatment over a number of years may lead to variability in an individual's response to treatment, called "motor fluctuations." Another form of motor fluctuation is uncontrolled writhing movement of the body or a limb, which is called "dyskinesia." 40% will develop motor fluctuations within six years of treatment.
Slide 11-

Drug Targets DA is made from the amino acid L-tyrosine. DA is inactivated after release by reuptake. It can be repackaged or degraded by MAO-A & B and COMT.
Slide 12-

Levodopa Levodopa is rapidly absorbed from the small intestine. Most patients experience improvement in symptoms about 30 minutes after a dose, and the benefit lasts about 3-5 hours. Food (in particular, protein-rich food) delays absorption of levodopa. Instruct patients to take levodopa 1 hour before meals. Levodopa is also available in a "controlled-release" (CR or SR) formulation. Controlled release levodopa provides a longer duration of action by increasing the time it takes for the gastrointestinal tract to absorb levodopa. However, CR only allows 70% of the levodopa to be absorbed by the gastrointestinal tract Levodopa preparations Standard release preparationscarbidopa/levodopa (Sinemet®): 10/100, 25/100, or 25/250 tablets Extended release preparationslevodopa/carbiopa (Sinemet CR®): 25/100 or 50/200 tablets Side effects include nausea, vomiting, dry mouth, dyskinesias, and dizziness. In some individuals, levodopa may cause confusion, hallucinations, or psychosis.
Slide 13-

Catechol-O-methyl transferase (COMT) inhibitors Like carbidopa, COMT inhibitors prevent the breakdown of levodopa which prolongs the duration of action of a dose of levodopa. COMT inhibitors may be prescribed when an individual experiences "wearing off," particularly when dopamine agonists (see below) are not tolerated. Entacapone (Comtan®)--available in the United States and many other countries.200 mg tablets usually given with each dose of levodopa. Side effects include diarrhea, vivid dreams, visual hallucinations, drowsiness, urine discoloration, and dyskinesias. Fulminant hepatic failure has been reported in are patients receiving tolcapone (Tasmar®).
Slide 14-

Combined carbidopa, levodopa and entacapone This preparation combines all 3 medications in one pill, which may be more convenient but may not be as flexible as taking the medications individually. Doses: Stalevo® 50: 50 mg levodopa, 12.5 mg carbidopa, and 200 mg entacapone Stalevo® 100: 100 mg levodopa, 25 mg caridopa and 200 mg entacapone Stalevo® 150: 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone Side effects of this combined preparation are the same as for levodopa and entacapone and include: diarrhea, vivid dreams, visual hallucinations, drowsiness, urine discoloration and dyskinesias.
Slide 15-

Dopamine agonists They may be used in place of levodopa or in combination with it. Cause less motor fluctuations. More likely to cause a number of side effects (such as nausea, somnolence, sleep attacks, postural hypotension, hallucinations, neuropsychiatric disorders, and lower extremity edema), particularly in patients over 70 and those with baseline cognitive deficits.
Slide 16-

Dopamine agonists Bromocriptine and pergolide (Permax ®) are ergot derivatives. May rarely cause retroperitoneal, pulmonary and pericardial fibrosis. Many reports of significant cardiac valve dysfunction requiring replacement due to pergolide. Pramipexole (Mirapex ®) and ropinirole (Requip ®) are not ergot compounds. Can be used in early Parkinson's disease and reduce the severity of symptoms. One side effect is daytime sleepiness and "sleep attacks." Although this may occur with all of the dopamine agonists (and levodopa), it was first appreciated in people treated with pramipexole.
Slide 17-

Dopamine agonists The response to a particular dopamine agonist is idiosyncratic. If one dopamine agonists does not offer benefit or causes bothersome side effects, another agonist may be tried. Treatment with dopamine agonists often begins at a very low dose. The dose is increased at intervals (depending on the agent) until benefit occurs.
Slide 18-

The case for starting treatment with a dopamine agonist Less dyskinesias 10%-20% versus 31%-45% during the first 2 to 5 years of treatment. Less wearing off 24% versus 38%. Dopamine agonists may slow the progression of Parkinson's disease. During a 4 year study of patients with early PD treated with levodopa or pramipexole, those patients treated with pramipexole may experience neuroprotection of dopamine-releasing neurons as demonstrated by SPECT. Those treated with ropinirole lost less fluorodopa signal than those treated with levodopa over the course of the study as documented by PET scanning. Trade off: More frequent side effects (drowsiness, hallucinations, generalized swelling and leg swelling).
Slide 19-

Other medications Amantadine Reduces fatigue and tremor and dyskinesias. Amantadine (Symmetrel®) as 100 mg capsules or in liquid form. Side effects may include difficulty concentrating, confusion, insomnia, nightmares, agitation, headache, hallucinations, edema and livedo reticularis. Anticholinergic medications Reduce tremor and/or rigidity. Benztropine mesylate (Cogentin®): 0.5 mg, 1 mg, 2 mg tablets or Trihexyphenidyl (Artane®): 2 mg and 5 mg tablets as well as liquid form. Side effects may include dry mouth, blurred vision, sedation, delirium, hallucination, constipation, and difficulty urinating. Selegiline MAO-B (monoamine oxidase B) inhibitor prolonging the action of dopamine in the brain. It also has a mild antidepressant effect. Eldepryl®: 5 mg capsule. Side effects may include heartburn, nausea, dry mouth, insomnia and dizziness. Confusion, nightmares, hallucinations, and headache occur less frequently and should be reported to your doctor. Rasagiline (Agilect ®) Soon to be released DA (MAO-B inhibitor) taken once daily in doses of 0.5 or 1 mg.
Slide 20-

Deep Brain Stimulation Unlike lesion procedures, DBS leaves electrodes in place in the brain to deliver continuous stimulation. Adjusting the stimulator and medications after electrode implantation is a major time commitment on the part of the neurological team and patient. Risks for DBS procedures include surgical risks (hemorrhage, infection) as well as hardware complications. These include leads breaking, electrode malfunction, stimulator failure and battery failure. Subthalamic Deep Brain Stimulation (DBS) improves dyskinesias and off time. It allows for a reduction in medication. Neuropsychiatric adverse events have been increasingly reported. Depression Suicide
Slide 21-

Deep Brain Stimulation
Slide 22-

Essential Tremor Typically a postural tremor, but it may be accentuated by goal-directed movements and may be present at rest. Flexion-extension movements at the wrist or adduction-abduction movements of the fingers or pronation-supination seen. Alcohol ameliorates tremor. Often there is a family history. No features of PD present. Check thyroid.
Slide 23-

Videos Parkinsonism Tardive dyskinesia UPDRS
Slide 24-

Progressive Supranuclear Palsy ALL OF THESE FEATURES Onset at age 40 or later Progressive course Bradykinesia Impaired vertical gaze (voluntary downgaze <15o) PLUS THREE OF THESE FEATURES Frequent falls as an early manifestation Prominent axial rigidity (neck rigidity > limb rigidity) Neck hyperextended Early dysarthria Dysphagia Lack of tremor May see frontal lobe dementia
Slide 25-

Multiple Systems Atrophy Three presentations: Shy-Drager Syndrome Akinetic, rigid parkinsonism with early and prominent autonomic dysfunction (urinary incontinence, postural hypotension, upper airway obstruction, arrhythmias). Striatonigral Degeneration Akinetic, rigid parkinsonism unresponsive to L-dopa. Olivopontocerebellar Atrophy Parkinsonism and cerebellar ataxia.
Slide 26-

Corticobasal Ganglionic Degeneration Rigid-bradykinetic parkinsonism with cortical signs: Apraxia Cortical sensory loss Alien hand phenomenon Asymmetric onset, dystonic limb postures, myoclonus, and L-dopa unresponsiveness are features
Slide 27-

Lewy Body Dementia & Alzheimer’s disease with Lewy Bodies Pathologically Lewy bodies can be seen with AD pathology or they can cause a dementia by themselves. LBD = dementia, fluctuating level of awareness, visual hallucinations, parkinsonism, and sensitivity to neuroleptics It is common to see parkinsonism develop in patients with AD.
Slide 28-

Myoclonus Sudden, shock-like muscle contractions Random and irregular Common manifestations: Action myoclonus Induced by voluntary movement Seen with metabolic abnormalities, metabolic encephalopathy, lithium toxicity, CJD… Lance-Adams syndrome Action myoclonus seen after cerebral anoxia Asterixis negative myoclonus (brief lapses of posture) seen in metabolic encephalopathy